Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients
Status:
Terminated
Trial end date:
2019-01-25
Target enrollment:
Participant gender:
Summary
The proposed randomized, open label, with treat as usual control group (standard treatment or
any disease modifying drugs), crossover phase II study will be conducted in 40 patients (n=20
per group) with the relapsing forms of multiple sclerosis according to the McDonald 2010
Criteria.
Patients will be randomized into 2 intervention groups. One will receive the FMT from month 1
and for the first 6 months (early intervention group). On the other hand, the other group
will be a control group during the first 6 months and will receive the FMT for the last 6
months of the study. Patients will be screened for eligibility based on MS diagnosis and EDSS
and if eligible then consented. All qualified patients will not be currently or recently
treated with high dose steroids.